Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Biotie Therapies Oyj : Change in the number of votes relating to Biotie Therapies Corp.'s shares

   Biotie Therapies Oyj : Change in the number of votes relating to Biotie
                           Therapies Corp.'s shares

Biotie Therapies Corp.          Stock Exchange Release    4 March 2013 at
11.30 a.m.

Change in the number of votes relating to Biotie Therapies Corp.'s shares

The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"),
Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie
Therapies Holding AG) has conveyed Biotie shares against consideration
pursuant to the option programs as follows:

               February 2013 Total (5/2011-     Options % of the total
                                    2/2013) outstanding      amount of
                    30,680        6,594,588   7,962,603           1.8%

The conveyance of Biotie shares relates to the option plan of Synosia
Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia")
acquired by Biotie in February 2011. According to such Synosia share option
plan, options have been granted to employees, former directors and
consultants. In connection with the completion of the acquisition of Synosia,
the option plan was amended so that instead of shares in Synosia an aggregate
maximum of 14,912,155 shares in Biotie may be subscribed based on the plan.
Biotie issued these 14,912,155 shares to its current subsidiary Synosia in
connection with the acquisition to be further conveyed to the option holders
when they potentially exercise their option rights in accordance with the
terms and conditions of the option program.

The conveyed shares previously held by the Company's subsidiary have not
carried any voting rights. The parent company Biotie does not own any treasury
shares. The conveyance does not affect the number of registered shares.

After the conveyances the changes are as follows:

 The increase of vote of  A total amount of The number of the The total number
             the Company     voting rights:   Company's share    of registered
           February 2013                                 held           shares
                                                 by the Group
                                                February 2013
                  30,680        444,393,171                        452,710,738

Turku, 4 March 2013

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900

NASDAQ OMX Helsinki Ltd
Main Media  


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Biotie Therapies Oyj via Thomson Reuters ONE
Sponsored Links
Sponsored Links